{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:55:15Z","timestamp":1792648515106,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41581-025-01000-w","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:42:09Z","timestamp":1757594529000},"page":"859-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Guidelines for the use of economic evaluation to inform policies around access to treatment for kidney failure"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-2065","authenticated-orcid":false,"given":"Siobhan","family":"Botwright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panji Fortuna","family":"Hadisoemarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinanti Khansa","family":"Chavarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7665-909X","authenticated-orcid":false,"given":"Aye Nandar","family":"Myint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-4205","authenticated-orcid":false,"given":"Brandon Wen Bing","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kridsada","family":"Chareonrungrueangchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8944-6225","authenticated-orcid":false,"given":"Chotika","family":"Suwanpanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitsinee","family":"Supapol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Edoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-8135","authenticated-orcid":false,"given":"Valerie","family":"Luyckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-0472","authenticated-orcid":false,"given":"Martin I.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-2930","authenticated-orcid":false,"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"1000_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","volume":"385","author":"S Hariharan","year":"2021","unstructured":"Hariharan, S., Israni, A. K. & Danovitch, G. Long-term survival after kidney transplantation. N. Engl. J. Med. 385, 729\u2013743 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1000_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-020-0315-4","volume":"16","author":"J Himmelfarb","year":"2020","unstructured":"Himmelfarb, J., Vanholder, R., Mehrotra, R. & Tonelli, M. The current and future landscape of dialysis. Nat. Rev. Nephrol. 16, 573\u2013585 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1000_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow, J. S. et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 52, 98\u2013107 (2021).","journal-title":"Am. J. Nephrol."},{"key":"1000_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2018.12.005","volume":"95","author":"DCH Harris","year":"2019","unstructured":"Harris, D. C. H. et al. Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int. 95, S1\u2013S33 (2019).","journal-title":"Kidney Int."},{"key":"1000_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 20, 473\u2013485 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1000_CR6","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage, T. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385, 1975\u20131982 (2015).","journal-title":"Lancet"},{"key":"1000_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2215\/CJN.09070620","volume":"16","author":"M Lunney","year":"2021","unstructured":"Lunney, M. et al. Availability, accessibility, and quality of conservative kidney management worldwide. Clin. J. Am. Soc. Nephrol. 16, 79\u201387 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1000_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/ckj\/sfx152","volume":"11","author":"G Kaur","year":"2018","unstructured":"Kaur, G. et al. Cost of hemodialysis in a public sector tertiary hospital of India. Clin. Kidney J. 11, 726\u2013733 (2018).","journal-title":"Clin. Kidney J."},{"key":"1000_CR9","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2214-109X(17)30057-8","volume":"5","author":"G Ashuntantang","year":"2017","unstructured":"Ashuntantang, G. et al. Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: a systematic review. Lancet Glob. Health 5, e408\u2013e417 (2017).","journal-title":"Lancet Glob. Health"},{"key":"1000_CR10","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/S2214-109X(15)00322-8","volume":"4","author":"WA Olowu","year":"2016","unstructured":"Olowu, W. A. et al. Outcomes of acute kidney injury in children and adults in sub-Saharan Africa: a systematic review. Lancet Glob. Health 4, e242\u2013e250 (2016).","journal-title":"Lancet Glob. Health"},{"key":"1000_CR11","doi-asserted-by":"publisher","unstructured":"Jamison, D. T. et al. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edn Vol. 9 (World Bank, 2017); https:\/\/doi.org\/10.1596\/978-1-4648-0527-1.","DOI":"10.1596\/978-1-4648-0527-1"},{"key":"1000_CR12","doi-asserted-by":"publisher","first-page":"m82","DOI":"10.1136\/bmj.m82","volume":"368","author":"Y Teerawattananon","year":"2020","unstructured":"Teerawattananon, Y., Dabak, S. V., Khoe, L. C., Bayani, D. B. S. & Isaranuwatchai, W. To include or not include: renal dialysis policy in the era of universal health coverage. BMJ 368, m82 (2020).","journal-title":"BMJ"},{"key":"1000_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.semnephrol.2017.02.007","volume":"37","author":"VA Luyckx","year":"2017","unstructured":"Luyckx, V. A., Miljeteig, I., Ejigu, A. M. & Moosa, M. R. Ethical challenges in the provision of dialysis in resource-constrained environments. Semin. Nephrol. 37, 273\u2013286 (2017).","journal-title":"Semin. Nephrol."},{"key":"1000_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/nep.13935","volume":"26","author":"IG Okpechi","year":"2021","unstructured":"Okpechi, I. G. et al. Building optimal and sustainable kidney care in low resource settings: the role of healthcare systems. Nephrology 26, 948\u2013960 (2021).","journal-title":"Nephrology"},{"key":"1000_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000321524","volume":"117","author":"IJ Katz","year":"2010","unstructured":"Katz, I. J., Gerntholtz, T. & Naicker, S. Africa and nephrology: the forgotten continent. Nephron Clin. Pract. 117, 320\u2013327 (2010).","journal-title":"Nephron Clin. Pract."},{"key":"1000_CR16","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.kisu.2019.11.004","volume":"10","author":"W Van Biesen","year":"2020","unstructured":"Van Biesen, W. et al. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney Int. Suppl. 10, e63\u2013e71 (2020).","journal-title":"Kidney Int. Suppl."},{"key":"1000_CR17","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., Torrance, G. W. Methods for the Economic Evaluation of Health Care Programmes. Oxford Univ. Press2015."},{"key":"1000_CR18","unstructured":"World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities: Main Findings. https:\/\/iris.who.int\/bitstream\/handle\/10665\/375063\/9789241509749-eng.pdf?sequence=1 (2015)."},{"key":"1000_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jval.2023.04.004","volume":"26","author":"DD Kim","year":"2023","unstructured":"Kim, D. D. et al. Developing criteria for health economic quality evaluation tool. Value Health 26, 1225\u20131234 (2023).","journal-title":"Value Health"},{"key":"1000_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro, J. J., Briggs, A. H., Siebert, U. & Kuntz, K. M. Modeling good research practices \u2014 overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health 15, 796\u2013803 (2012).","journal-title":"Value Health"},{"key":"1000_CR21","doi-asserted-by":"publisher","unstructured":"Edwards, R. T. & McIntosh, E. (eds). Applied Health Economics for Public Health Practice and Research (Oxford Univ. Press, 2019); https:\/\/doi.org\/10.1093\/med\/9780198737483.001.0001.","DOI":"10.1093\/med\/9780198737483.001.0001"},{"key":"1000_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0140-6736(01)06107-4","volume":"358","author":"MI Meltzer","year":"2001","unstructured":"Meltzer, M. I. Introduction to health economics for physicians. Lancet 358, 993\u2013998 (2001).","journal-title":"Lancet"},{"key":"1000_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","volume":"15","author":"M Roberts","year":"2012","unstructured":"Roberts, M. et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Health 15, 804\u2013811 (2012).","journal-title":"Value Health"},{"key":"1000_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.7196\/SAMJ.2021.v111i7.15395","volume":"111","author":"M Davies","year":"2021","unstructured":"Davies, M. & Cassimjee, Z. Provision of long-term renal replacement therapy to non-national patients in South Africa. South. Afr. Med. J. 111, 615 (2021).","journal-title":"South. Afr. Med. J."},{"key":"1000_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.vhri.2019.10.004","volume":"21","author":"T Thaweethamcharoen","year":"2020","unstructured":"Thaweethamcharoen, T., Sritippayawan, S., Noparatayaporn, P. & Aiyasanon, N. Cost-utility analysis of continuous ambulatory peritoneal dialysis and automated peritoneal dialysis for Thai patients with end-stage renal disease. Value Health Reg. Issues 21, 181\u2013187 (2020).","journal-title":"Value Health Reg. Issues"},{"key":"1000_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/nep.13830","volume":"26","author":"DBS Bayani","year":"2021","unstructured":"Bayani, D. B. S. et al. Filtering for the best policy: an economic evaluation of policy options for kidney replacement coverage in the Philippines. Nephrology 26, 170\u2013177 (2021).","journal-title":"Nephrology"},{"key":"1000_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/TP.0000000000002910","volume":"104","author":"B Li","year":"2020","unstructured":"Li, B. et al. Equity\u2013efficiency trade-offs associated with alternative approaches to deceased donor kidney allocation: a patient-level simulation. Transplantation 104, 795\u2013803 (2020).","journal-title":"Transplantation"},{"key":"1000_CR28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13696998.2019.1588738","volume":"22","author":"B Spinowitz","year":"2019","unstructured":"Spinowitz, B. et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J. Med. Econ. 22, 593\u2013604 (2019).","journal-title":"J. Med. Econ."},{"key":"1000_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ckj\/sfab126","volume":"15","author":"D Gupta","year":"2022","unstructured":"Gupta, D. et al. Peritoneal dialysis \u2014 first initiative in India: a cost-effectiveness analysis. Clin. Kidney J. 15, 128\u2013135 (2022).","journal-title":"Clin. Kidney J."},{"key":"1000_CR30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jval.2023.02.009","volume":"26","author":"AW Erbe","year":"2023","unstructured":"Erbe, A. W., Kendzia, D., Busink, E., Carroll, S. & Aas, E. Value of an integrated home dialysis model in the United Kingdom: a cost-effectiveness analysis. Value Health 26, 984\u2013994 (2023).","journal-title":"Value Health"},{"key":"1000_CR31","unstructured":"Chalkidou, K., Culyer, A. J. & Nemzoff, C. Perspective in Economic Evaluations of Health Care Interventions in Low- and Middle-Income Countries \u2014 One Size Does Not Fit All. https:\/\/www.cgdev.org\/sites\/default\/files\/perspective-economic-evaluations-healthcare-interventions-low-and-middle-income.pdf (Center for Global Development, 2018)."},{"key":"1000_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-024-00552-1","volume":"22","author":"M Sittimart","year":"2024","unstructured":"Sittimart, M. et al. An overview of the perspectives used in health economic evaluations. Cost. Eff. Resour. Alloc.22, 41 (2024).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1000_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond, M. et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12, 409\u2013418 (2009).","journal-title":"Value Health"},{"key":"1000_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"F Sassi","year":"2006","unstructured":"Sassi, F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 21, 402\u2013408 (2006).","journal-title":"Health Policy Plan."},{"key":"1000_CR35","doi-asserted-by":"publisher","unstructured":"Donnelly, J. Comparative effectiveness research (updated). Health Aff. (Millwood) https:\/\/doi.org\/10.1377\/hpb20101008.552571 (2010).","DOI":"10.1377\/hpb20101008.552571"},{"key":"1000_CR36","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1377\/hlthaff.2021.00343","volume":"40","author":"LZ Rand","year":"2021","unstructured":"Rand, L. Z. & Kesselheim, A. S. Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review. Health Aff. 40, 1402\u20131410 (2021).","journal-title":"Health Aff."},{"key":"1000_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40273-014-0216-0","volume":"33","author":"A Beresniak","year":"2015","unstructured":"Beresniak, A. et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 33, 61\u201369 (2015).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0167-6296(97)00005-2","volume":"16","author":"S Anand","year":"1997","unstructured":"Anand, S. & Hanson, K. Disability-adjusted life years: a critical review. J. Health Econ. 16, 685\u2013702 (1997).","journal-title":"J. Health Econ."},{"key":"1000_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40273-024-01410-x","volume":"42","author":"EM Tomeny","year":"2024","unstructured":"Tomeny, E. M. et al. Rethinking tuberculosis morbidity quantification: a systematic review and critical appraisal of TB disability weights in cost-effectiveness analyses. Pharmacoeconomics 42, 1209\u20131236 (2024).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR40","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.319.7222.1423","volume":"319","author":"T Arnesen","year":"1999","unstructured":"Arnesen, T. & Nord, E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ 319, 1423\u20131425 (1999).","journal-title":"BMJ"},{"key":"1000_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders, G. D. et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316, 1093\u20131103 (2016).","journal-title":"JAMA"},{"key":"1000_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","volume":"5","author":"D Sharma","year":"2021","unstructured":"Sharma, D., Aggarwal, A. K., Downey, L. E. & Prinja, S. National healthcare economic evaluation guidelines: a cross-country comparison. Pharmacoecon. Open. 5, 349\u2013364 (2021).","journal-title":"Pharmacoecon. Open."},{"key":"1000_CR43","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462322000186","volume":"38","author":"C Daccache","year":"2022","unstructured":"Daccache, C., Karam, R., Rizk, R., Evers, S. M. A. A. & Hiligsmann, M. The development process of economic evaluation guidelines in low- and middle-income countries: a systematic review. Int. J. Technol. Assess. Health Care 38, e35 (2022).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"1000_CR44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40273-016-0414-z","volume":"34","author":"S Verguet","year":"2016","unstructured":"Verguet, S., Kim, J. J. & Jamison, D. T. Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics 34, 913\u2013923 (2016).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-12-18","volume":"12","author":"OF Norheim","year":"2014","unstructured":"Norheim, O. F. et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost. Eff. Resour. Alloc. 12, 18 (2014).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1000_CR46","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/ndt\/gfz278","volume":"35","author":"ME Elsayed","year":"2020","unstructured":"Elsayed, M. E., Morris, A. D., Li, X., Browne, L. D. & Stack, A. G. Propensity score matched mortality comparisons of peritoneal and in-centre haemodialysis: systematic review and meta-analysis. Nephrol. Dial. Transplant. 35, 2172\u20132182 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1000_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/08968608221140788","volume":"43","author":"P-T Luo","year":"2023","unstructured":"Luo, P.-T. et al. Impact of peritoneal dialysis modality on patient and PD survival: a systematic review. Perit. Dial. Int. 43, 128\u2013138 (2023).","journal-title":"Perit. Dial. Int."},{"key":"1000_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-023-03435-4","volume":"25","author":"S Chander","year":"2024","unstructured":"Chander, S. et al. Mortality and mode of dialysis: meta-analysis and systematic review. BMC Nephrol. 25, 1 (2024).","journal-title":"BMC Nephrol."},{"key":"1000_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000536648","volume":"70","author":"L Cheng","year":"2024","unstructured":"Cheng, L., Hu, N., Song, D. & Chen, Y. Mortality of peritoneal dialysis versus hemodialysis in older adults: an updated systematic review and meta-analysis. Gerontology 70, 461\u2013478 (2024).","journal-title":"Gerontology"},{"key":"1000_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000484115","volume":"42","author":"L Zazzeroni","year":"2017","unstructured":"Zazzeroni, L., Pasquinelli, G., Nanni, E., Cremonini, V. & Rubbi, I. Comparison of quality of life in patients undergoing hemodialysis and peritoneal dialysis: a systematic review and meta-analysis. Kidney Blood Press. Res. 42, 717\u2013727 (2017).","journal-title":"Kidney Blood Press. Res."},{"key":"1000_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012277","volume":"8","author":"AS Chauhan","year":"2023","unstructured":"Chauhan, A. S. et al. Validating the rigour of adaptive methods of economic evaluation. BMJ Glob. Health 8, e012277 (2023).","journal-title":"BMJ Glob. Health"},{"key":"1000_CR52","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/ndt\/gft214","volume":"28","author":"AN Karopadi","year":"2013","unstructured":"Karopadi, A. N., Mason, G., Rettore, E. & Ronco, C. Cost of peritoneal dialysis and haemodialysis across the world. Nephrol. Dial. Transplant. 28, 2553\u20132569 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1000_CR53","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.kint.2016.08.024","volume":"90","author":"AR Ready","year":"2016","unstructured":"Ready, A. R., Nath, J., Milford, D. V., Adu, D. & Jewitt-Harris, J. Establishing sustainable kidney transplantation programs in developing world countries: a 10-year experience. Kidney Int. 90, 916\u2013920 (2016).","journal-title":"Kidney Int."},{"key":"1000_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12962-024-00545-0","volume":"22","author":"C Nemzoff","year":"2024","unstructured":"Nemzoff, C. et al. Rapid cost-effectiveness analysis: hemodialysis versus peritoneal dialysis for patients with acute kidney injury in Rwanda. Cost. Eff. Resour. Alloc. 22, 35 (2024).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1000_CR55","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","volume":"19","author":"T Wilkinson","year":"2016","unstructured":"Wilkinson, T. et al. The international decision support initiative reference case for economic evaluation: an aid to thought. Value Health 19, 921\u2013928 (2016).","journal-title":"Value Health"},{"key":"1000_CR56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema, A. E., Brouwer, W. B. F. & Claxton, K. Discounting in economic evaluations. Pharmacoeconomics 36, 745\u2013758 (2018).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/heapol\/czaa073","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker, M., Hallett, T. B. & Atun, R. On discount rates for economic evaluations in global health. Health Policy Plan. 35, 107\u2013114 (2020).","journal-title":"Health Policy Plan."},{"key":"1000_CR58","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/heapol\/czaa073","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker, M., Hallett, T. B. & Atun, R. On time horizons in health economic evaluations. Health Policy Plan. 35, 1237\u20131243 (2020).","journal-title":"Health Policy Plan."},{"key":"1000_CR59","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jval.2017.10.003","volume":"21","author":"CU Adeagbo","year":"2018","unstructured":"Adeagbo, C. U., Rattanavipapong, W., Guinness, L. & Teerawattananon, Y. The development of the guide to economic analysis and research (GEAR) online resource for low- and middle-income countries\u2019 health economics practitioners: a commentary. Value Health 21, 569\u2013572 (2018).","journal-title":"Value Health"},{"key":"1000_CR60","first-page":"673","volume":"10","author":"MY Bertram","year":"2021","unstructured":"Bertram, M. Y., Lauer, J. A., Stenberg, K. & Edejer, T. T. T. Methods for the economic evaluation of health care interventions for priority setting in the health system: an update from WHO CHOICE. Int. J. Health Policy Manag. 10, 673\u2013677 (2021).","journal-title":"Int. J. Health Policy Manag."},{"key":"1000_CR61","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada 4th edn. https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf (2017)."},{"key":"1000_CR62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejor.2020.06.043","volume":"289","author":"A Harper","year":"2021","unstructured":"Harper, A., Mustafee, N. & Yearworth, M. Facets of trust in simulation studies. Eur. J. Oper. Res. 289, 197\u2013213 (2021).","journal-title":"Eur. J. Oper. Res."},{"key":"1000_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","volume":"26","author":"JE Stahl","year":"2008","unstructured":"Stahl, J. E. Modelling methods for pharmacoeconomics and health technology assessment. Pharmacoeconomics 26, 131\u2013148 (2008).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR64","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","volume":"32","author":"U Siebert","year":"2012","unstructured":"Siebert, U. et al. State-transition modeling. Med. Decis. Mak. 32, 690\u2013700 (2012).","journal-title":"Med. Decis. Mak."},{"key":"1000_CR65","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jval.2024.07.027","volume":"27","author":"M Soares","year":"2024","unstructured":"Soares, M. et al. Recommendations on the use of structured expert elicitation protocols for healthcare decision making: a good practices report of an ISPOR task force. Value Health 27, 1469\u20131478 (2024).","journal-title":"Value Health"},{"key":"1000_CR66","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1185\/030079906X167327","volume":"23","author":"R Goeree","year":"2007","unstructured":"Goeree, R. et al. Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Curr. Med. Res. Opin. 23, 671\u2013682 (2007).","journal-title":"Curr. Med. Res. Opin."},{"key":"1000_CR67","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1016\/j.vaccine.2014.12.050","volume":"33","author":"Y Teerawattananon","year":"2015","unstructured":"Teerawattananon, Y. & Tritasavit, N. A learning experience from price negotiations for vaccines. Vaccine 33, A11\u2013A12 (2015).","journal-title":"Vaccine"},{"key":"1000_CR68","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","volume":"22","author":"HC Turner","year":"2019","unstructured":"Turner, H. C., Lauer, J. A., Tran, B. X., Teerawattananon, Y. & Jit, M. Adjusting for inflation and currency changes within health economic studies. Value Health 22, 1026\u20131032 (2019).","journal-title":"Value Health"},{"key":"1000_CR69","unstructured":"Vassall, A. et al. Reference Case for Estimating the Costs of Global Health Services and Interventions. https:\/\/ghcosting.org\/pages\/standards\/reference_case (2017)."},{"key":"1000_CR70","unstructured":"NICE Decision Support Unit. Survival Analysis TSD. https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/survival-analysis (2022)."},{"key":"1000_CR71","doi-asserted-by":"crossref","unstructured":"Coyle, D., Haines, A. & Lee, K. Extrapolating Clinical Evidence within Economic Evaluations: CADTH Methods and Guidelines (Canadian Agency for Drugs and Technologies in Health, 2023); https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594389\/.","DOI":"10.51731\/cjht.2023.649"},{"key":"1000_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177436","volume":"12","author":"Afiatin","year":"2017","unstructured":"Afiatin et al. Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia. PLoS ONE12, e0177436 (2017).","journal-title":"PLoS ONE"},{"key":"1000_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001307","volume":"9","author":"M Wyld","year":"2012","unstructured":"Wyld, M., Morton, R. L., Hayen, A., Howard, K. & Webster, A. C. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med. 9, e1001307 (2012).","journal-title":"PLoS Med."},{"key":"1000_CR74","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1524-4733.2007.00308.x","volume":"11","author":"YS Liem","year":"2008","unstructured":"Liem, Y. S., Bosch, J. L. & Hunink, M. G. M. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health 11, 733\u2013741 (2008).","journal-title":"Value Health"},{"key":"1000_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12955-020-01449-2","volume":"18","author":"A Chuasuwan","year":"2020","unstructured":"Chuasuwan, A., Pooripussarakul, S., Thakkinstian, A., Ingsathit, A. & Pattanaprateep, O. Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis. Health Qual. Life Outcomes 18, 191 (2020).","journal-title":"Health Qual. Life Outcomes"},{"key":"1000_CR76","first-page":"A4796","volume":"61","author":"CE Jensen","year":"2014","unstructured":"Jensen, C. E., S\u00f8rensen, P. & Petersen, K. D. In Denmark kidney transplantation is more cost-effective than dialysis. Dan. Med. J. 61, A4796 (2014).","journal-title":"Dan. Med. J."},{"key":"1000_CR77","doi-asserted-by":"publisher","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021) Disability Weights (Institute for Health Metrics and Evaluation, 2024); https:\/\/doi.org\/10.6069\/485b-dx41.","DOI":"10.6069\/485b-dx41"},{"key":"1000_CR78","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/0272989X211045070","volume":"42","author":"J Bilcke","year":"2022","unstructured":"Bilcke, J. & Beutels, P. Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice. Med. Decis. Mak. 42, 421\u2013435 (2022).","journal-title":"Med. Decis. Mak."},{"key":"1000_CR79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan, S. D. et al. Budget impact analysis \u2014 principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17, 5\u201314 (2014).","journal-title":"Value Health"},{"key":"1000_CR80","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf, J. A. et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices \u2014 budget impact analysis. Value Health 10, 336\u2013347 (2007).","journal-title":"Value Health"},{"key":"1000_CR81","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs, A. H. et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6. Value Health 15, 835\u2013842 (2012).","journal-title":"Value Health"},{"key":"1000_CR82","doi-asserted-by":"publisher","first-page":"238146832110634","DOI":"10.1177\/23814683211063418","volume":"6","author":"H-F Chen","year":"2021","unstructured":"Chen, H.-F. et al. The magnitude of the health and economic impact of increased organ donation on patients with end-stage renal disease. MDM Policy Pract. 6, 23814683211063418 (2021).","journal-title":"MDM Policy Pract."},{"key":"1000_CR83","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/ajt.14702","volume":"18","author":"DA Axelrod","year":"2018","unstructured":"Axelrod, D. A. et al. An economic assessment of contemporary kidney transplant practice. Am. J. Transplant. 18, 1168\u20131176 (2018).","journal-title":"Am. J. Transplant."},{"key":"1000_CR84","unstructured":"NICE. in NICE Health Technology Evaluations: The Manual (National Institute for Health and Care Excellence, 2023)."},{"key":"1000_CR85","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala, P., Ochalek, J., Leech, A. A. & Tong, T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics 36, 509\u2013522 (2018).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2024.100927","volume":"13","author":"W Isaranuwatchai","year":"2024","unstructured":"Isaranuwatchai, W. et al. An empirical study looking at the potential impact of increasing cost-effectiveness threshold on reimbursement decisions in Thailand. Health Policy Technol. 13, 100927 (2024).","journal-title":"Health Policy Technol."},{"key":"1000_CR87","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram, M. Y. et al. Cost\u2013effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925 (2016).","journal-title":"Bull. World Health Organ."},{"key":"1000_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2023.01.010","volume":"36","author":"D Mangoya","year":"2023","unstructured":"Mangoya, D., Barham, L., Moyo, E., Moyo, P. & Dzinamarira, T. The use of economic evaluation tools in essential health benefits package selection for universal health coverage. Value Health Reg. Issues 36, 1\u20139 (2023).","journal-title":"Value Health Reg. Issues"},{"key":"1000_CR89","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12962-020-00255-3","volume":"19","author":"GT Eregata","year":"2021","unstructured":"Eregata, G. T. et al. Generalised cost-effectiveness analysis of 159 health interventions for the Ethiopian essential health service package. Cost. Eff. Resour. Alloc. 19, 2 (2021).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1000_CR90","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2019.11.005","volume":"75","author":"MH Eckman","year":"2020","unstructured":"Eckman, M. H., Woodle, E. S., Thakar, C. V., Alloway, R. R. & Sherman, K. E. Cost-effectiveness of using kidneys from HCV-viremic donors for transplantation into HCV-uninfected recipients. Am. J. Kidney Dis. 75, 857\u2013867 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1000_CR91","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere, A., Drummond, M., Palacios, A., Garcia-Marti, S. & Augustovski, F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob. Health 11, e833\u2013e842 (2023).","journal-title":"Lancet Glob. Health"},{"key":"1000_CR92","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40258-022-00730-3","volume":"20","author":"C Sampson","year":"2022","unstructured":"Sampson, C. et al. Supply-side cost-effectiveness thresholds: questions for evidence-based policy. Appl. Health Econ. Health Policy 20, 651\u2013667 (2022).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"1000_CR93","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1467-9876.2011.01014.x","volume":"61","author":"M Strong","year":"2012","unstructured":"Strong, M., Oakley, J. E. & Chilcott, J. Managing structural uncertainty in health economic decision models: a discrepancy approach. J. R. Stat. Soc. Ser. C. Appl. Stat. 61, 25\u201345 (2012).","journal-title":"J. R. Stat. Soc. Ser. C. Appl. Stat."},{"key":"1000_CR94","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40273-018-0693-7","volume":"36","author":"H Haji Ali Afzali","year":"2018","unstructured":"Haji Ali Afzali, H., Bojke, L. & Karnon, J. Model structuring for economic evaluations of new health technologies. Pharmacoeconomics 36, 1309\u20131319 (2018).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR95","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-statistics-040120-010730","volume":"9","author":"CH Jackson","year":"2022","unstructured":"Jackson, C. H. et al. Value of information analysis in models to inform health policy. Annu. Rev. Stat. Appl. 9, 95 (2022).","journal-title":"Annu. Rev. Stat. Appl."},{"key":"1000_CR96","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40258-022-00747-8","volume":"20","author":"S Senanayake","year":"2022","unstructured":"Senanayake, S., Healy, H., McPhail, S. M., Baboolal, K. & Kularatna, S. Cost-effectiveness and budget impact analysis of implementing a \u2018Soft Opt-Out\u2019 system for kidney donation in Australia. Appl. Health Econ. Health Policy 20, 769\u2013779 (2022).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"1000_CR97","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40273-022-01207-w","volume":"41","author":"S Botwright","year":"2023","unstructured":"Botwright, S., Win, E. M., Kapol, N., Benjawan, S. & Teerawattananon, Y. Cost-utility analysis of universal maternal pertussis immunisation in Thailand: a comparison of two model structures. Pharmacoeconomics 41, 77\u201391 (2023).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR98","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","volume":"23","author":"C Rothery","year":"2020","unstructured":"Rothery, C. et al. Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force. Value Health 23, 277\u2013286 (2020).","journal-title":"Value Health"},{"key":"1000_CR99","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","volume":"23","author":"E Fenwick","year":"2020","unstructured":"Fenwick, E. et al. Value of information analysis for research decisions \u2014 an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health 23, 139\u2013150 (2020).","journal-title":"Value Health"},{"key":"1000_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-6-52","volume":"6","author":"E Fenwick","year":"2006","unstructured":"Fenwick, E., Marshall, D. A., Levy, A. R. & Nichol, G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv. Res. 6, 52 (2006).","journal-title":"BMC Health Serv. Res."},{"key":"1000_CR101","doi-asserted-by":"crossref","unstructured":"Jackson, C., et al. A guide to value of information methods for prioritising research in health impact modelling. Epidemiol. Methods 10, 20210012.","DOI":"10.1515\/em-2021-0012"},{"key":"1000_CR102","unstructured":"Health Intervention and Technology Assessment Program. Guidelines comparison. Guide to Economic Analysis and Research (GEAR) Online Resource. https:\/\/www.gear4health.com\/gear\/health-economic-evaluation-guidelines (2024)."},{"key":"1000_CR103","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips, Z., Bojke, L., Sculpher, M., Claxton, K. & Golder, S. Good practice guidelines for decision-analytic modelling in health technology assessment. Pharmacoeconomics 24, 355\u2013371 (2006).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR104","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau, D. et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics 40, 601\u2013609 (2022).","journal-title":"Pharmacoeconomics"},{"key":"1000_CR105","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy, D. M. et al. Model transparency and validation. Med. Decis. Mak. 32, 733\u2013743 (2012).","journal-title":"Med. Decis. Mak."},{"key":"1000_CR106","unstructured":"World Health Organization. Value-based Pricing: WHO Guideline on Country Pharmaceutical Pricing Policies. A Plain Language Summary. https:\/\/iris.who.int\/bitstream\/handle\/10665\/341896\/9789240024595-eng.pdf (2021)."},{"key":"1000_CR107","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.transproceed.2011.06.006","volume":"43","author":"J Dom\u00ednguez","year":"2011","unstructured":"Dom\u00ednguez, J., Harrison, R. & Atal, R. Cost\u2013benefit estimation of cadaveric kidney transplantation: the case of a developing country. Transpl. Proc. 43, 2300\u20132304 (2011).","journal-title":"Transpl. Proc."},{"key":"1000_CR108","doi-asserted-by":"publisher","first-page":"765","DOI":"10.36740\/WLek202404123","volume":"77","author":"SM Hryshchuk","year":"2024","unstructured":"Hryshchuk, S. M. & Parii, V. D. Cost-effectiveness of dialysis and kidney transplantation to treat end-stage renal disease in Ukraine. Wiad. Lekarskie 77, 765\u2013771 (2024).","journal-title":"Wiad. Lekarskie"},{"key":"1000_CR109","doi-asserted-by":"publisher","first-page":"733","DOI":"10.4103\/1319-2442.160175","volume":"26","author":"D Rosselli","year":"2015","unstructured":"Rosselli, D., Rueda, J.-D. & Diaz, C. Cost-effectiveness of kidney transplantation compared with chronic dialysis in end-stage renal disease. Saudi J. Kidney Dis. Transplant. 26, 733 (2015).","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"1000_CR110","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cegh.2019.07.001","volume":"8","author":"A Moradpour","year":"2020","unstructured":"Moradpour, A., Hadian, M. & Tavakkoli, M. Economic evaluation of end stage renal disease treatments in Iran. Clin. Epidemiol. Glob. Health 8, 199\u2013204 (2020).","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"1000_CR111","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11255-022-03402-2","volume":"55","author":"Z Hong","year":"2022","unstructured":"Hong, Z. et al. Economic evaluation of three dialysis methods in patients with end-stage renal disease in China. Int. Urol. Nephrol. 55, 1247\u20131254 (2022).","journal-title":"Int. Urol. Nephrol."},{"key":"1000_CR112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.14740\/jocmr2817w","volume":"9","author":"E Pike","year":"2017","unstructured":"Pike, E., Hamidi, V., Ringerike, T., Wisloff, T. & Klemp, M. More use of peritoneal dialysis gives significant savings: a systematic review and health economic decision model. J. Clin. Med. Res. 9, 104\u2013116 (2017).","journal-title":"J. Clin. Med. Res."},{"key":"1000_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-022-06252-4","volume":"15","author":"S Putri","year":"2022","unstructured":"Putri, S. et al. Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model. BMC Res. Notes 15, 359 (2022).","journal-title":"BMC Res. Notes"},{"key":"1000_CR114","unstructured":"Sinclair, A. et al. Dialysis Modalities for the Treatment of End-Stage Kidney Disease: A Health Technology Assessment. CADTH Optimal Use Report No. 6.2b (Canadian Agency for Drugs and Technologies in Health, 2017); https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531991\/."},{"key":"1000_CR115","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/nep.12668","volume":"21","author":"F Yang","year":"2016","unstructured":"Yang, F., Lau, T. & Luo, N. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. Nephrology 21, 669\u2013677 (2016).","journal-title":"Nephrology"},{"key":"1000_CR116","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/0896860819893812","volume":"40","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Financial implications of dialysis modalities in the developing world: a Chinese perspective. Perit. Dial. Int. 40, 193\u2013201 (2020).","journal-title":"Perit. Dial. Int."},{"key":"1000_CR117","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1093\/ndt\/gfq780","volume":"26","author":"M Haller","year":"2011","unstructured":"Haller, M., Gutjahr, G., Kramar, R., Harnoncourt, F. & Oberbauer, R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol. Dial. Transplant. 26, 2988\u20132995 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1000_CR118","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3111\/13696998.2011.653512","volume":"15","author":"U Shimizu","year":"2012","unstructured":"Shimizu, U. et al. Cost-effectiveness achieved through changing the composition of renal replacement therapy in Japan. J. Med. Econ. 15, 444\u2013453 (2012).","journal-title":"J. Med. Econ."},{"key":"1000_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218422","volume":"14","author":"NK Surendra","year":"2019","unstructured":"Surendra, N. K. et al. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: hemodialysis versus continuous ambulatory peritoneal dialysis. PLoS ONE14, e0218422 (2019).","journal-title":"PLoS ONE"},{"key":"1000_CR120","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3747\/pdi.2011.00037","volume":"32","author":"G Villa","year":"2012","unstructured":"Villa, G. et al. Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit. Dial. Int. 32, 192\u2013199 (2012).","journal-title":"Perit. Dial. Int."},{"key":"1000_CR121","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40258-014-0108-7","volume":"12","author":"C Treharne","year":"2014","unstructured":"Treharne, C., Liu, F. X., Arici, M., Crowe, L. & Farooqui, U. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective. Appl. Health Econ. Health Policy 12, 409\u2013420 (2014).","journal-title":"Appl. Health Econ. Health Policy"},{"key":"1000_CR122","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039653","volume":"11","author":"F Yang","year":"2021","unstructured":"Yang, F., Liao, M., Wang, P. & Liu, Y. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China. BMJ Open. 11, e039653 (2021).","journal-title":"BMJ Open."},{"key":"1000_CR123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12882-024-03530-0","volume":"25","author":"M Yousefi","year":"2024","unstructured":"Yousefi, M., Rezaei, S., Hajebrahimi, S., Falsafi, N. & Keshvari-Shad, F. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective? BMC Nephrol. 25, 85 (2024).","journal-title":"BMC Nephrol."},{"key":"1000_CR124","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s12325-016-0408-4","volume":"33","author":"AT Beby","year":"2016","unstructured":"Beby, A. T., Cornelis, T., Zinck, R. & Liu, F. X. Cost-effectiveness of high dose hemodialysis in comparison to conventional in-center hemodialysis in the Netherlands. Adv. Ther. 33, 2032\u20132048 (2016).","journal-title":"Adv. Ther."},{"key":"1000_CR125","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jval.2014.10.002","volume":"18","author":"FX Liu","year":"2015","unstructured":"Liu, F. X., Treharne, C., Arici, M., Crowe, L. & Culleton, B. High-dose hemodialysis versus conventional in-center hemodialysis: a cost-utility analysis from a UK payer perspective. Value Health 18, 17\u201324 (2015).","journal-title":"Value Health"},{"key":"1000_CR126","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/CEOR.S109649","volume":"8","author":"F Ramponi","year":"2016","unstructured":"Ramponi, F. et al. Cost-effectiveness analysis of online hemodiafiltration versus high-flux hemodialysis. Clinicoecon. Outcomes Res. 8, 531\u2013540 (2016).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"1000_CR127","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vhri.2023.09.011","volume":"40","author":"J Augusty\u0144ska","year":"2024","unstructured":"Augusty\u0144ska, J. et al. Automated peritoneal dialysis with remote patient monitoring: clinical effects and economic consequences for Poland. Value Health Reg. Issues 40, 53\u201362 (2024).","journal-title":"Value Health Reg. Issues"},{"key":"1000_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164201","volume":"11","author":"MR Moosa","year":"2016","unstructured":"Moosa, M. R., Maree, J. D., Chirehwa, M. T. & Benatar, S. R. Use of the \u2018Accountability for Reasonableness\u2019 approach to improve fairness in accessing dialysis in a middle-income country. PLoS ONE11, e0164201 (2016).","journal-title":"PLoS ONE"},{"key":"1000_CR129","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.23325","volume":"5","author":"BA Kiberd","year":"2022","unstructured":"Kiberd, B. A., Tennankore, K. K. & Vinson, A. J. Comparing the net benefits of adult deceased donor kidney transplantation for a patient on the preemptive waiting list vs a patient receiving dialysis. JAMA Netw. Open 5, e2223325 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1000_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05736-y","volume":"20","author":"S Senanayake","year":"2020","unstructured":"Senanayake, S. et al. Deceased donor kidney allocation: an economic evaluation of contemporary longevity matching practices. BMC Health Serv. Res. 20, 931 (2020).","journal-title":"BMC Health Serv. Res."},{"key":"1000_CR131","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/TP.0000000000001057","volume":"100","author":"JM Smith","year":"2016","unstructured":"Smith, J. M. et al. Cost implications of new national allocation policy for deceased donor kidneys in the United States. Transplantation 100, 879\u2013885 (2016).","journal-title":"Transplantation"},{"key":"1000_CR132","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12882-020-1708-0","volume":"21","author":"CKH Wong","year":"2020","unstructured":"Wong, C. K. H. et al. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy. BMC Nephrol. 21, 42 (2020).","journal-title":"BMC Nephrol."},{"key":"1000_CR133","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/TP.0000000000003887","volume":"106","author":"DA Axelrod","year":"2022","unstructured":"Axelrod, D. A. et al. The clinical and economic benefit of CMV matching in kidney transplant: a decision analysis. Transplantation 106, 1227\u20131232 (2022).","journal-title":"Transplantation"},{"key":"1000_CR134","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001629","volume":"10","author":"RJ Bamforth","year":"2024","unstructured":"Bamforth, R. J. et al. Expanding access to high KDPI kidney transplant for recipients aged 60\u2009y and older: cost utility and survival. Transpl. Direct 10, e1629 (2024).","journal-title":"Transpl. Direct"},{"key":"1000_CR135","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.transproceed.2023.09.026","volume":"55","author":"TA Ellison","year":"2023","unstructured":"Ellison, T. A. et al. Evaluating cost-effectiveness in using high-kidney donor profile index organs. Transpl. Proc. 55, 2333\u20132344 (2023).","journal-title":"Transpl. Proc."},{"key":"1000_CR136","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001474","volume":"9","author":"JA Hedley","year":"2023","unstructured":"Hedley, J. A. et al. Cost-effectiveness of interventions to increase utilization of kidneys from deceased donors with primary brain malignancy in an Australian setting. Transpl. Direct 9, e1474 (2023).","journal-title":"Transpl. Direct"},{"key":"1000_CR137","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.14929","volume":"18","author":"M Kadatz","year":"2018","unstructured":"Kadatz, M., Klarenbach, S., Gill, J. & Gill, J. S. Cost-effectiveness of using kidneys from hepatitis C nucleic acid test-positive donors for transplantation in hepatitis C-negative recipients. Am. J. Transplant. 18, 2457\u20132464 (2018).","journal-title":"Am. J. Transplant."},{"key":"1000_CR138","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jval.2020.07.007","volume":"23","author":"S Senanayake","year":"2020","unstructured":"Senanayake, S. et al. Donor kidney quality and transplant outcome: an economic evaluation of contemporary practice. Value Health 23, 1561\u20131569 (2020).","journal-title":"Value Health"},{"key":"1000_CR139","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1097\/TP.0000000000004632","volume":"107","author":"KK Shah","year":"2023","unstructured":"Shah, K. K. et al. Cost-effectiveness of kidney transplantation from donors at increased risk of blood-borne virus infection transmission. Transplantation 107, 2028\u20132042 (2023).","journal-title":"Transplantation"},{"key":"1000_CR140","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12962-022-00390-z","volume":"20","author":"P Koto","year":"2022","unstructured":"Koto, P. et al. An ex-ante cost-utility analysis of the deemed consent legislation compared to expressed consent for kidney transplantations in Nova Scotia. Cost. Eff. Resour. Alloc. 20, 55 (2022).","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"1000_CR141","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.transproceed.2014.09.146","volume":"46","author":"MC Cavallo","year":"2014","unstructured":"Cavallo, M. C. et al. Cost-effectiveness of kidney transplantation from DCD in Italy. Transpl. Proc. 46, 3289\u20133296 (2014).","journal-title":"Transpl. Proc."},{"key":"1000_CR142","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2215\/CJN.03350313","volume":"8","author":"L Barnieh","year":"2013","unstructured":"Barnieh, L., Gill, J. S., Klarenbach, S. & Manns, B. J. The cost-effectiveness of using payment to increase living donor kidneys for transplantation. Clin. J. Am. Soc. Nephrol. 8, 2165\u20132173 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1000_CR143","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1177\/0272989X12455462","volume":"32","author":"J Karnon","year":"2012","unstructured":"Karnon, J. et al. Modeling using discrete event simulation. Med. Decis. Mak. 32, 701\u2013711 (2012).","journal-title":"Med. Decis. Mak."},{"key":"1000_CR144","unstructured":"Health Intervention and Technology Assessment Program. Plant-A-Tree \u2014 an open access decision tree builder. Guide to Economic Analysis and Research (GEAR) Online Resource. https:\/\/www.gear4health.com\/page\/i\/plant-a-tree (2024)."},{"key":"1000_CR145","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/ajkd.2000.8235","volume":"36","author":"BJ Manns","year":"2000","unstructured":"Manns, B. J., Taub, K. J. & Donaldson, C. Economic evaluation and end-stage renal disease: from basics to bedside. Am. J. Kidney Dis. 36, 12\u201328 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"1000_CR146","unstructured":"Glossary: Health Economic Terms. https:\/\/yhec.co.uk\/resources\/glossary\/ (York Health Economics Consortium, 2016)."},{"key":"1000_CR147","unstructured":"Glossary of Terms for Health Economics and Systematic Review. https:\/\/methods.cochrane.org\/economics\/sites\/methods.cochrane.org.economics\/files\/public\/uploads\/ccemg_website_glossary.pdf."},{"key":"1000_CR148","unstructured":"International Society of Nephrology. The ISN Framework for Developing Dialysis Programs in Low-Resource Settings. https:\/\/www.theisn.org\/wp-content\/uploads\/2021\/03\/ISN-Framework-Dialysis-Report-HIRES.pdf (2021)."},{"key":"1000_CR149","unstructured":"Bertram, M., Dhaene, G. & Tan-Torres Edejer, T. (eds). Institutionalizing Health Technology Assessment Mechanisms: A How to Guide. https:\/\/www.who.int\/publications\/i\/item\/9789240020665 (World Health Organization, 2021)."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01000-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:02:31Z","timestamp":1763384551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01000-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":149,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01000-w","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"19 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}